US 12,344,653 B2
Antigen binding molecules for small cell lung cancer
Paul Lampe, Seattle, WA (US); Ashley McGarry Houghton, Seattle, WA (US); and Kristin Lastwika, Seattle, WA (US)
Assigned to Fred Hutchinson Cancer Center, Seattle, WA (US)
Filed by FRED HUTCHINSON CANCER CENTER, Seattle, WA (US)
Filed on Sep. 18, 2020, as Appl. No. 17/025,991.
Claims priority of provisional application 62/903,546, filed on Sep. 20, 2019.
Prior Publication US 2021/0085716 A1, Mar. 25, 2021
Int. Cl. C07K 14/725 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61P 35/00 (2018.01); C07K 16/2896 (2013.01); C12N 5/0638 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method of treating small cell lung cancer (SCLC) in a subject that has been diagnosed with limited stage SCLC, the method comprising administering to the subject a chemotherapy regimen or an immunotherapy regimen to the subject, wherein the subject has been diagnosed with limited stage SCLC by:
(a) contacting a biological sample obtained from the subject with an array consisting essentially of antigens capable of specifically binding, respectively, to four autoantibodies, wherein the four autoantibodies are anti-GAD65 antibodies, anti-PTPRU antibodies, anti-TFRC antibodies, and anti-GABA-b antibodies;
(b) detecting an amount of the four autoantibodies present in the biological sample when the autoantibodies bind to the antigens in the array; and
(c) diagnosing limited stage SCLC in the subject when the amount of the four autoantibodies in the biological sample exceeds, respectively, a control amount.